Reactivation of Herpes Zoster Keratitis Following Shingrix Vaccine [PDF]
Case Reports in Ophthalmology, 2022 We present a case of herpes zoster keratitis reactivation shortly following the Shingrix vaccine. In our patient, reactivation of herpes zoster keratitis occurred a few weeks following the herpes zoster subunit (HZ/su) vaccine.
Tracy J. Lu, Christopher N. Ta
doaj +3 more sources
Myasthenia Gravis Exacerbation with Shingrix Vaccine [PDF]
RRNMF Neuromuscular Journal, 2020 ...
Digala, Lakshmi, Govindarjan, Raghav
core +4 more sources
Serious and Progressive Neuropathy Presumably Post-Shingrix Vaccination
Reports, 2023 We present a case of serious and progressive neuropathy shortly following the administration of the herpes zoster subunit (HZ/su) vaccine, otherwise known as Shingrix.
Michael J. Wons +3 more
doaj +2 more sources
Recombinant Zoster Vaccine (Shingrix): a nex gun for Rheumatologist [PDF]
Beyond Rheumatology, 2022 Herpes Zoster, or as commonly known shingles, is a debilitating painful rash occurring at any age in anyone caused by reactivation of the varicella zoster virus (VZV). The lifetime risk of HZ in the general population is around 30% HZ incidence increases
D. Marotto, P. Sarzi Puttini, A. Riva
doaj +2 more sources
Real-world data on the use of the Shingrix vaccine among patients with inflammatory arthritis and risk of cardiovascular events following herpes zoster [PDF]
Arthritis Research & TherapyBackground Risk of cardiovascular events may increase after herpes zoster; therefore, American College of Rheumatology guidelines strongly recommend vaccination against herpes zoster in patients aged ≥ 18 years with rheumatic and musculoskeletal diseases
Jeffrey R. Curtis +4 more
doaj +2 more sources
Varicella zoster virus mRNA vaccine candidate induced superior cellular immunity and comparable humoral and Fc-mediated immunity compared to the licensed subunit vaccine in a mouse model [PDF]
Human Vaccines & ImmunotherapeuticsThe threat of herpes zoster (HZ) is increasing, particularly in the elderly and immunocompromised individuals. Although two platform vaccines are currently available for HZ prevention, the low effectiveness of the live attenuated varicella-zoster virus ...
Eun-Jeong Jang +13 more
doaj +2 more sources
TLR9 and STING agonists adjuvanted varicella-zoster virus glycoprotein E induced a potent and durable nasal vaccine response [PDF]
Human Vaccines & ImmunotherapeuticsHerpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV), primarily affecting middle-aged and older individuals and often accompanied by severe pain and other complications. Vaccination is an effective preventive measure against
Jing-Xing Yang +13 more
doaj +2 more sources
Immunogenicity and cellular response of a herpes zoster virus gEgI fusion protein adjuvanted with CpG-emulsion in mice [PDF]
Journal of NanobiotechnologyHerpes zoster (HZ), commonly known as shingles, arises from the reactivation of the latent varicella-zoster virus (VZV) when VZV-specific cellular immunity declines below a critical threshold necessary for viral suppression.
Sibo Zhang +19 more
doaj +2 more sources
Herpes zoster infection in patients with inflammatory bowel disease [PDF]
The Korean Journal of Internal MedicinePatients with inflammatory bowel disease (IBD) are at increased risk of herpes zoster (HZ), particularly those receiving immunosuppressive treatments such as corticosteroids, thiopurines, and biologics, which elevate the likelihood of varicella-zoster ...
Dong Hyun Kim, Sang-Bum Kang
doaj +2 more sources
A novel adjuvant system BK-02 with CpG2006 and MF59 enhances the immunogenicity of a herpes zoster subunit vaccine [PDF]
Frontiers in ImmunologyIntroductionReactivation of the varicella-zoster virus (VZV) results in herpes zoster (HZ), which can lead to complications such as postherpetic neuralgia. The commercially available HZ subunit adjuvanted vaccine, Shingrix®, offers significant protection
Zihan Wang +16 more
doaj +2 more sources